SZodixStudyAcademic Library
ShelvesOpen access
Study · an open academic library·Metadata from OpenAlex (CC0)·Shelves·OpenAlex metadata, de-duplicated
Generic Medicine Pricing Policies in Europe: Current Status and Impact
9 references·1 citing·40 second hop
Generic Medicine Pricing Policies in Europe: Current Status and Impact (2010)Generic Medicine Pricing Policies in Euro…Impact of European Pharmaceutical Price Regulation on Generic Price Competition (2010)Impact of European Pharmaceut…Regulation and pricing of pharmaceuticals: Reference pricing or price cap regulation? (2008)Regulation and pricing of pha…International comparison of generic medicine prices (2007)International comparison of g…Sustaining Generic Medicines Markets in Europe (2006)Sustaining Generic Medicines …Do generics offer significant savings to the UK National Health Service? (2006)Do generics offer significant…Dynamic competition in pharmaceuticals (2004)Dynamic competition in pharma…The Relative Importance of Actual and Potential Competition: Empirical Evidence From the Pharmaceuticals Market (2003)The Relative Importance of Ac…Cross-national price differences for pharmaceuticals: how large, and why? (2000)Cross-national price differen…A comparative analysis of generics markets in five European countries (2000)A comparative analysis of gen…Drug tendering: drug supply and shortage implications for the uptake of biosimilars (2017)Drug tendering: drug supply a…Does Regulation Drive Out Competition in Pharmaceutical Markets? (2000)Generic Drug Industry Dynamics (2005)Pharmaceutical policies: effects of reference pricing, other pricing, and purchasing policies (2006)Does the Market Share of Generic Medicines Influence the Price Level? (2011)Pharmaceutical Prices under Regulation: Tiered Co-payments and Reference Pricing in Germany (2012)Biosimilars: How Can Payers Get Long-Term Savings? (2016)Brand Loyalty, Entry, and Price Competition in Pharmaceuticals after the 1984 Drug Act (1992)Generic Entry and the Pricing of Pharmaceuticals (1997)Generic Entry and the Pricing of Pharmaceuticals (1997)Generic medicines: Greek physicians’ perceptions and prescribing practices (2009)Initiatives to enhance the quality and efficiency of statin and PPI prescribing in the UK: impact and implications (2010)Empirical studies of innovation and market structure (1989)Dynamic count data models of technological innovation (1994)Determinants of branded prescription medicine prices in OECD countries (2011)Supply chain agility and firm performance: testing serial mediations in pharmaceutical industry (2023)The Role of Investment in Entry-Deterrence (1980)Contestable Markets and the Theory of Industry Structure (1982)Contestable Markets and the Theory of Industry Structure (1982)Pharmaceutical policies: effects of reference pricing, other pricing, and purchasing policies (2014)Reference pricing with endogenous generic entry (2016)Review of the literature on reference pricing (2000)Encouraging the use of generic medicines: implications for transition economies. (2002)Competition in off-patent drug markets: Issues, regulation and evidence (2008)Physician Agency and Adoption of Generic Pharmaceuticals (2012)The experiences of implementing generic medicine policy in eight countries: A review and recommendations for a successful promotion of generic medicine use (2013)Male-Female Wage Differentials in Urban Labor Markets (1973)Labor Market Discrimination Against Hispanic and Black Men (1983)The Hedonic Method (2003)Parallel imports and the pricing of pharmaceutical products: evidence from the European Union (2004)Risk sharing arrangements for pharmaceuticals: potential considerations and recommendations for European payers (2010)American Society of Clinical Oncology Identifies Five Key Opportunities to Improve Care and Reduce Costs: The Top Five List for Oncology (2012)Drug Shortages: A Complex Health Care Crisis (2014)Estimating the Effect of Training Programs on Earnings (1978)Evaluating the Effect of Teachers’ Group Performance Incentives on Pupil Achievement (2002)Reference pricing of pharmaceuticals (2006)Effects of Reference Pricing in Pharmaceutical Markets (2010)What are the obstacles to generic substitution? An assessment of the behaviour of prescribers, patients and pharmacies during the first year of generic substitution in Sweden (2004)Impact of a generic substitution reform on patients’ and society's expenditure for pharmaceuticals (2006)Pharmaceutical Pricing Policies in a Global Market (2008)European countries with small populations can obtain low prices for drugs: Lithuania as a case history (2011)
this work references cited by second hop

References

  • 2000Cross-national price differences for pharmaceuticals: how large, and why?285 cited
  • 2006Sustaining Generic Medicines Markets in Europe161 cited
  • 2008Regulation and pricing of pharmaceuticals: Reference pricing or price cap regulation?153 cited
  • 2000A comparative analysis of generics markets in five European countries127 cited
  • 2010Impact of European Pharmaceutical Price Regulation on Generic Price Competition114 cited
  • 2007International comparison of generic medicine prices86 cited
  • 2004Dynamic competition in pharmaceuticals85 cited
  • 2003The Relative Importance of Actual and Potential Competition: Empirical Evidence From the Pharmaceuticals Market84 cited
  • 2006Do generics offer significant savings to the UK National Health Service?79 cited

Cited by

  • 2017Drug tendering: drug supply and shortage implications for the uptake of biosimilars67 cited

Only edges whose both ends are imported exist here. Widen the year window, or show the whole map. Back to the work